|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007595,
umls-concept:C0008838,
umls-concept:C0008971,
umls-concept:C0086418,
umls-concept:C0146224,
umls-concept:C0206664,
umls-concept:C0449445,
umls-concept:C0599739,
umls-concept:C0678133,
umls-concept:C0680242,
umls-concept:C1707689,
umls-concept:C1709793
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
1994-10-28
|
|
pubmed:abstractText |
Cisplatin-based induction chemotherapy may achieve a complete response (i.e., no sign of tumor following treatment) in 70%-80% of patients with germ cell tumors. However, only a minority of patients in whom the firstline regimens fail are cured with the salvage regimens.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
19
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1517-24
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7932806-Antineoplastic Agents,
pubmed-meshheading:7932806-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7932806-Camptothecin,
pubmed-meshheading:7932806-Cisplatin,
pubmed-meshheading:7932806-Computer Simulation,
pubmed-meshheading:7932806-Dose-Response Relationship, Drug,
pubmed-meshheading:7932806-Drug Administration Schedule,
pubmed-meshheading:7932806-Drug Antagonism,
pubmed-meshheading:7932806-Drug Synergism,
pubmed-meshheading:7932806-Etoposide,
pubmed-meshheading:7932806-Humans,
pubmed-meshheading:7932806-Paclitaxel,
pubmed-meshheading:7932806-Teratocarcinoma,
pubmed-meshheading:7932806-Topotecan,
pubmed-meshheading:7932806-Tumor Cells, Cultured,
pubmed-meshheading:7932806-Vincristine
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
|
|
pubmed:affiliation |
Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
